Next generation bacitracin: reimagining a classic antibiotic
Buijs, N.P.

Citation
Buijs, N. P. (2023, December 20). *Next generation bacitracin: reimagining a classic antibiotic*. Retrieved from https://hdl.handle.net/1887/3674234

Synthetic studies with bacitracin A

Abstract

The growing threat of drug-resistant bacteria is a global concern, highlighting the urgent need for new antibiotics and antibacterial strategies. In this light, practical synthetic access to natural product antibiotics can provide important structure-activity insights while also opening avenues for the development of novel analogues with improved properties. To this end, we here report an optimised synthetic route for the preparation of the clinically used macrocyclic peptide antibiotic bacitracin. Our combined solid- and solution-phase approach addresses the problematic, and previously unreported, formation of undesired epimers associated with the stereochemically fragile N-terminal thiazoline moiety. These results provide insights into the synthesis of bacitracin A and highlights the potential for further modification of this scaffold to develop novel antibiotics with enhanced properties.

Introduction

The accelerating appearance of antimicrobial resistance (AMR) is a growing global public health risk. In 2019 nearly 1.3 million deaths could be directly attributed to AMR.[1] Despite the increasing need for new antibacterial agents, only two mechanistically novel classes of antibiotics have been approved in the last 40 years, namely, linezolid and daptomycin.[2] As the prevalence of multi-drug resistant bacteria grows, the need to develop new and more potent antibacterial agents is greater than ever.[3] In this light, natural product antibiotics remain a rich source of structural and mechanistic diversity. One such example is bacitracin which comprises a family of structurally similar macrocyclic peptides, the most well-known of which is bacitracin A (**1**, **Fig. 1A**).[4] Produced by strains of *Bacillus lichenformis* and *Bacillus subtilis,* bacitracin exhibits activity against Gram-positive bacteria.[5] The moderate activity and systemic toxicity of bacitracin A have restricted its use to topical applications, where it is often formulated along with neomycin and polymyxin B, for the treatment of minor cuts and burns.[5,6] Notably, while bacitracin has been used widely in both the pharmaceutical and livestock industries for over 70 years, little occurrence of problematic resistance has been reported during this time.[7]

Structurally, bacitracin A is a 12-mer macrocyclic peptide consisting of both L- and D-amino acids, and is biosynthesised by a dedicated nonribosomal peptide synthetase.[8] The macrocycle is formed via an amide linkage between the side chain of Lys6 and the peptide C-terminus. The N-terminus of bacitracin A contains an unusual aminothiazoline motif generated by the enzymatic condensation of L-cysteine and L-isoleucine.[7] The N-terminal amine is critical for antibiotic activity given that bacitracin F, a degradation product of bacitracin A formed by


Figure 1. (A) Structure of Bacitracin A (**1**). **(B)** Crystal structure of bacitracin A complexed with geranyl-pyrophosphate ($C_{10}PP$) mediated by Zn^{2+} (green) and Na^+ (light blue). Adapted from PDB ID: 4K7T.[13]

the oxidative deamination of the aminothiazoline to give the corresponding ketothiazole, is inactive.[4,9] Mechanistically, bacitracin functions in a manner distinct from all other antibiotics that target bacterial cell wall biosynthesis. Specifically, in the presence of a divalent metal ion, most commonly Zn^{2+}, bacitracin binds to and sequesters the membrane-associated phospholipid isoprenyl pyrophosphate ($C_{55}PP$).[10,11] Given that $C_{55}PP$ does not play a role in mammalian cell metabolism, it presents a target unique to bacteria with great promise for antibiotic development.[11,12]

Recent structural studies by Loll and co-workers revealed that bacitracin A forms a well-defined ternary 1:1:1 antibiotic-Zn^{2+}-lipid complex (along with a flanking Na^+ ion) clearly illustrating how $C_{55}PP$ is bound while also explaining the Zn^{2+}-dependence of bacitracin's antibiotic activity (**Fig. 1B**).[13,14] Also of note is the finding that in the context of the ternary complex, the side chains of the hydrophobic residues at positions 1, 3, 5, 8, and 9 align to form a face that presumably interacts with the bacterial membrane, while the polar side chains of residues 2, 4, 7, 10, 11, and 12 are in turn exposed to the aqueous environment.

The combination of bacitracin's unique mechanism of action and low incidence of resistance, as well as the structural limitations that prevent its wider clinical application, make it an appealing scaffold for variation. This prompted us to undertake investigations into the synthesis of bacitracin A with the goal of generating novel analogues that maintain the unique antibiotic activity of the parent compound while also addressing its structural liabilities.

Results and Discussion

The solid-phase total synthesis of Bacitracin A was first reported by Griffin and co-workers in 1996[15] and we began our investigation by attempting to reproduce the published synthesis (**Scheme 1**). This commenced with Rink amide resin loaded with an allyl protected aspartic acid building block coupled via its side chain carboxylate (corresponding to the C-terminal Asn12 residue) after which nine successive Fmoc-SPPS cycles were applied to yield the linear decapeptide intermediate. Of note, installation of the residue corresponding to Lys6 was performed using Fmoc-Lys(Alloc)-OH. Subsequent on-resin treatment of the peptide with Pd(PPh$_3$)$_4$ led to the simultaneous removal of the Alloc and Ally ester groups at Lys6 and Asn12 respectively. The partially protected peptide was then treated with BOP/DIPEA, which smoothly mediated the formation of the peptide macrocycle. As shown in **Scheme 1A**, the next step in the synthesis called for coupling of Boc-protected aminothiazoline building block **5**. However, our attempts at reproducing the synthesis of thiazoline dipeptide **5** were

plagued by racemisation of the thiazoline stereocenter during the final saponification step (**Scheme 1B**). While the methyl ester precursor **4** was cleanly formed in high stereochemical purity, in our hands the reported hydrolysis conditions employing LiOH consistently generated a mixture of diastereomers. Attempted separation of the diastereomers by means of silica gel column chromatography only made matters worse as further stereochemical scrambling was found to occur under these conditions. While no mention of this issue was included in the 1996 publication, recent reports describing the synthesis of structurally similar thiazoline containing carboxylic acids do make note of their propensity to epimerise under a variety of conditions.[16] After exploring a number of options, we were pleased to find that this issue could be overcome by applying a mild and selective method for hydrolysing methyl esters previously reported by the Nicolaou group.[17] Specifically, treatment of thiazoline methyl ester **4** with trimethyltin hydroxide led to complete conversion within two hours, after which a convenient aqueous workup to remove tin salts, providing the desired product in a purity suitable to avoid the need for silica chromatography (**Scheme 1B**).

With access to the amino thiazoline carboxylic acid **5** in stereochemically pure form, the synthesis of bacitracin A was continued. To this end, we applied the previously described

Scheme 1. (A) Synthesis of bacitracin A with reported thiazoline coupling conditions.[15] **(B)** Optimised synthesis of thiazoline carboxylic acid **5**.

conditions employing a double coupling of **5**, first with HATU, then with PyBOP/HOBt, to the resin-bound peptide macrocycle. However, following resin cleavage and global deprotection by treatment with TFA, LC-MS analysis indicated the presence of four peaks of similar intensity and all with the same mass as bacitracin A, which we subsequently labelled BacA$_{A-D}$, based on the order in which they eluted (**Fig. 2**). Notably, BacA$_D$ (the last eluting species) was found to have the same retention time as naturally occuring bacitracin A obtained from commercial sources.

These findings led us to surmise that four diastereomeric species are formed as a result of the activation of **5** in the presence of base, which can cause epimerisation of the α-position, along with the subsequent TFA treatment, which in turn can cause scrambling of the isoleucine α-position (see **Scheme S1** for proposed mechanism of base- and acid-mediated epimerisation). While not mentioned in the original bacitracin synthesis, such pathways are


Figure 2. Analytical HPLC traces of co-injections of four bacitracin A diastereomers and purified commercially available bacitracin A of natural origin.

in line with other reports describing the susceptibility of bacitracin's thiazoline moiety, and thiazolines in general, to racemisation.[16,18–20]

To evaluate the antibacterial properties of the different bacitracin diastereomers, the four species were first separated using preparative HPLC. The antibacterial activities of $BacA_{A-D}$ were assessed in a minimum inhibitory concentration (MIC) assay run against a panel of representative Gram-positive bacterial strains. An *E. coli* strain was also included in the MIC panel as a representative Gram-negative organism. Of note, the media used in the MIC assay was supplemented with 0.3 mM $ZnSO_4$ to provide the divalent metal ion required for bacitracin's activity.[21] The activity of the four $BacA_{A-D}$ diastereomers was compared to that of commercially sourced bacitracin A as well as to vancomycin, which served as a positive control. The results of the MIC assay are summarised in **Table 1** and reveal that of the four diastereomers, $BacA_D$ matches the potency of the natural product, a result in keeping with the co-elution study (**Fig. 2**), while the other three diastereomers all exhibit significantly reduced antimicrobial activity. Based on these results it was concluded that the $BacA_D$ diastereomer corresponds to the natural product. To further confirm this, we next turned to NMR spectroscopy wherein both 1- and 2-D NMR experiments revealed the spectra of the $BacA_D$ diastereomer to be identical to that of bacitracin A (**Fig. 3**, **Table S1–S2**).

In an attempt to optimise the synthesis of bacitracin A we turned our attention to minimising the formation of the unwanted diastereomers associated with the stereochemical scrambling of the aminothiazoline moiety. To do so we first investigated the acidic conditions used for resin cleavage and global deprotection. As noted above, we suspected that under acidic

Table 1. Minimum inhibitory concentration (MIC) values for bacitracin A diastereomers compared with bacitracin A, vancomycin and polymyxin B.

Compound	S. aureus ATCC 29213	S. aureus USA300 (MRSA)	S. aureus VRS3b (VRSA)	B. subtilis 168	S. simulans 22	E. faecium E980	E. faecium E155 (vanA)	E. faecium E7314 (vanB)	E. coli ATCC 25922
$BacA_A$	>64	>64	>64	>64	8	>64	>64	>64	>64
$BacA_B$	16	16	>64	64	1	32	32	32	>64
$BacA_C$	>64	>64	>64	>64	2	>64	>64	>64	>64
$BacA_D$	2	2	>64	32	0.25	16	2	16	>64
BacA natural[b]	2	2	>64	32	0.25	16	2	8	>64
Vancomycin	1	2	>64	0.25	0.5	0.5	>64	64	-
Polymyxin B	-	-	-	-	-	-	-	-	2

[a]MIC values displayed in µg mL[-1] and measured in Lysogeny broth (LB) supplemented with 0.3 mM $ZnSO_4$. [b]Purified commercially available bacitracin A of natural origin.

Figure 3. Overlaid expansion ¹H NMR of Bacitracin A of natural origin (top) and BacA$_D$ of synthetic origin (bottom). Spectra recorded in DMSO-d_6 (850 MHz). Full assignment is provided in supplementary **Table S1** and **Table S2**.

conditions the α-position of the N-terminal Ile residue involved in the aminothiazoline moiety could be prone to racemisation. In fact, the capacity for acid treatment of bacitracin A to cause formation of a "low potency" isomeric form of bacitracin was first reported in 1961 by Konigsberg *et al.*[22] To further explore this phenomenon we therefore treated commercially sourced, pure bacitracin A with the same acidic cleavage cocktail (95:2.5:2.5 TFA/TIPS/H$_2$O) used in the final SPPS step. This study revealed that under these conditions bacitracin A converts to a new species with the same mass and a retention time corresponding to the BacA$_B$ diastereomer previously isolated (**Fig. 4**). Notably, this was found to be a time-dependent process resulting in near complete epimerisation after 2 hours while at 30 minutes epimerisation was assessed to be >15%. Given this insight, we therefore opted to use a 30-minute cleavage in our subsequent bacitracin syntheses, which facilitated >95% deprotection while effectively minimising epimerisation at the Ile1 position.


Figure 4. **(A)** Acid mediated epimerisation of purified bacitracin A after treatment with 95% TFA, 2.5% TIPS and 2.5% water (*v/v/v*) over time. **(B)** Percentage epimerisation of purified bacitracin A over time.

We next examined the conditions used for activation and coupling thiazoline building block **5** to the resin-bound peptide. As also previously mentioned, the stereochemical integrity of the α-position corresponding to Cys2 of the thiazoline motif was found to be very susceptible to basic conditions. In addition to the published conditions, a variety of other common coupling agents were also explored and found to give similar scrambling. This lead us ultimately to investigate the use of the milder peptide coupling agent COMU, a uronium salt derived from Oxyma.[23] A key advantage of COMU over other peptide coupling reagents is that it incorporates a hydrogen bond accepting oxygen atom in its iminium moiety, allowing for the use of a single equivalent of base. Gratifyingly, when paired with the sterically hindered 2,2,6,6,-tetramethylpiperidine (TMP), COMU was found to be very effective at supressing base-promoted epimerisation. This was reflected in the marked decrease in the formation of the BacA$_A$ and BacA$_C$ diastereomers as evidenced by HPLC analysis of the crude product.

This further supports the notion the undesired BacA$_A$ and BacA$_C$ diastereomers correspond to bacitracin A variants bearing the incorrect *S*-configuration at the Cys2 α-position of the thiazoline moiety. Collectively, the use of COMU/TMP for the coupling of thiazoline **5**, along with the optimised cleavage and deprotection conditions, resulted in effective suppression of the unwanted diastereomers. Compared to the previously published route which yields a mixture of four bacitracin diastereomers in similar quantities, our optimised conditions result in the formation of bacitracin A as the major species (**Scheme 2**).

Scheme 2. Optimised synthesis conditions of bacitracin A (**1**) leading to the suppression of diastereomer by-products illustrated with HPLC analysis. The optimised conditions result in formation of the desired BacA$_D$ as the major species (blue trace) in contrast to the diastereomeric mixture obtained when using the previously published conditions (black trace).

Our findings also provide insights into the relative importance of stereochemistry in bacitracin's N-terminal aminothiazoline motif. It appears that the *R*-configuration at the Cys2-derived α-position is essential as the BacA$_A$ and BacA$_C$ diastereomers, both bearing an *S*-configuration at this position, are devoid of activity. By comparison, the BacA$_B$ diastereomer wherein the Ile1-derived α-position is inverted but the Cys2-derived α-position is the same as for bacitracin A, retains some antibacterial activity, albeit much less than the natural product (**Table 1**). It is perhaps not surprising that the Cys2 stereocenter is more critical for antibacterial activity. As is evident in the crystal structure of bacitracin A bound to zinc and geranyl-pyrophosphate (**Fig. 1B**), the sp^2 nitrogen of the thiazoline and adjacent N-terminal amino group are both actively involved in zinc binding. The Cys2 stereocentre plays a key role in setting the orientation of the aminothiazoline moiety and it stands to reason that the incorrect configuration at this centre would severely impacts its capacity to contribute to the zinc chelation essential to bacitracin's activity.

Conclusions

In summary, we have developed an optimised protocol for the synthesis of bacitracin A that circumvents previously unaddressed stereochemical issues associated with the N-terminal aminothiazoline moiety. This optimised combined solid- and solution-phase approach suppresses the formation of unwanted stereoisomers resulting in a higher yield and more convenient purification of the desired bacitracin A species. Notably, the improved synthetic route here described provides access to the bacitracin scaffold with confidence in the stereochemical purity of the product. Future work will be aimed at applying this improved route to investigate the effects of other structural variations throughout the bacitracin framework to generate new SAR insights.

Experimental Procedures

All reagents employed were of American Chemical Society (ACS) grade or higher and were used without further purification unless otherwise stated. HPLC-grade acetonitrile, peptide grade *N,N*-dimethylformamide (DMF) and dichloromethane (DCM) for peptide synthesis were purchased from Biosolve Chimie SARL and VWR, respectively. Unless otherwise stated, ^{1}H NMR and ^{13}C NMR spectra were recorded on a Bruker AV-400 spectrometer. The chemical shifts are noted as δ-values in parts per million (ppm) relative to the signal of CDCl$_3$ for ^{1}H NMR (δ = 7.26 ppm) and relative to the solvent signal of CDCl$_3$ for ^{13}C NMR (δ = 77.16 ppm). Coupling constants (*J*) are given in Hz.

HPLC analyses were performed on a Shimadzu Prominence-i LC-2030 system with a Dr. Maisch ReproSil Gold 120 C18 column (4.6 × 250 mm, 10 μm) at 30 °C and equipped with a UV detector monitoring at 214 and 254 nm. The following solvent system, at a flow rate of 1 mL/min, was used: solvent A (0.1 % TFA in water/acetonitrile 95:5); solvent B (0.1 % TFA in water/acetonitrile 5:95). Gradient elution was as follows: 100:0 (A/B) for 2 min, 100:0 to 0:100 (A/B) over 23 min, 0:100 (A/B) for 1 min, then reversion back to 100:0 (A/B) over 1 min, 100:5 (A/B) for 4 min.

LC-MS analysis were performed on a Shimadzu LC-20AD system with a Shimadzu ShimPack GISS-HP C18 column (3.0 x 150 mm, 3 μm) at 30°C and equipped with a UV detector. As solvent system, at a flow rate of 0.5 mL/min, solvent A (0.1% formic acid in water) and solvent B (acetonitrile) was used. Gradient elution was as follows: 95:5 A/B for 2 min, 95:5 to 0:100 A/B over 13 min, 0:100 A/B for 2 min, then reversion back to 95:5 A/B over 1 min, 95:5 A/B for 3 min. This system was connected to a Shimadzu 8040 triple quadrupole mass spectrometer (ESI ionisation).

High resolution mass spectra (HRMS) were recorded on a Shimadzu Nexera X2 UHPLC system with a Waters Acquity HSS C18 column (2.1 × 100 mm, 1.8 μm) at 30 °C and equipped with a diode array detector. The following solvent system, at a flow rate of 0.5 mL/min, was used: solvent A, 0.1 % formic acid in water; solvent B, 0.1 % formic acid in acetonitrile. Gradient elution was as follows: 95:5 (A/B) for 1 min, 95:5 to 15:85 (A/B) over 6 min, 15:85 to 0:100 (A/B) over 1 min, 0:100 (A/B) for 3 min, then reversion back to 95:5 (A/B) for 3 min. This system was connected to a Shimadzu 9030 QTOF mass spectrometer (ESI ionisation) calibrated internally with Agilent's API-TOF reference mass solution kit (5.0 mM purine, 100.0 mM ammonium trifluoroacetate and 2.5 mM hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazine) diluted to achieve a mass count of 10000.

Chemical Synthesis

N-Boc-ʟ-isoleucinyl amide (3)[24]

To a solution of *N*-Boc-ʟ-isoleucine **2** (5.04 g, 21.6 mmol) and *N*-methylmorpholine (2.86 mL, 25.9 mmol) in DME (100 mL) at 0 °C was added isobutyl chloroformate (3.37 mL, 25.9 mmol). After stirring for 2 minutes, an aqueous solution of ammonia (25 wt%, 10 mL) was added. The solution was allowed to reach room temperature and stirred for 2 hours under an inert atmosphere. The reaction mixture was then diluted with H$_2$O (100 mL) and extracted using DCM (3 × 100 mL). The organic layers were combined and were washed using 1 M HCl (3 × 300 mL) and brine (300 mL). The organic layer was dried over Na$_2$SO$_4$, filtered and concentrated under reduced pressure. The crude residue was thoroughly dried under high vacuum to afford **3** (4.34 g, 87%) as a white solid. ^{1}H NMR (400 MHz, CDCl$_3$) δ 6.27 (s, 1H CON*HH*), 5.88 (s, 1H, CON*HH*), 5.15 (d, *J* = 8.8 Hz, 1H, NH), 4.01 (t, *J* = 7.7 Hz, 1H, CH), 1.91–1.77 (m, 1H, C*HH*), 1.59–1.45 (m, 1H, CH*H*), 1.43 (s, 9H, C(CH$_3$)$_3$), 1.18–1.05 (m, 1H, C*HH*), 0.95 (d, *J* = 6.8 Hz, 3H, CHC*H$_3$*), 0.90 (t, *J* = 7.4 Hz, 3H, CH$_2$C*H$_3$*). ^{13}C NMR (101 MHz, CDCl$_3$) δ 174.5 (C), 156.0 (C), 80.1 (C), 58.9 (CH), 37.2 (CH), 28.4 ((CH$_3$)$_3$), 24.8 (CH$_2$), 15.7 (CH$_3$), 11.5 (CH$_3$). HRMS (ESI) *m/z*: [M+H]$^+$ calculated C$_{11}$H$_{22}$N$_2$O$_3$: 231.1703, found: 231.1704.

Methyl (*R*)-2-[1'(*S*)-(*tert*-butoxycarbonylamino)-2'(*S*)-methylbutyl]- Δ²-thiazoline -4-carboxylate (4)[25]

Triethyloxonium hexafluorophosphate (5.32 g, 21.4 mmol) was dissolved in DCM (20 mL), cooled to 0 °C and added to a solution of **3** (4.30 g, 18.7 mmol) in anhydrous DCM (26.7 mL) at 0 °C. The resulting slurry was then allowed to reach room temperature and stirred 18 hours under an inert atmosphere. After full conversion by TLC, the now clear solution was diluted with DCM (50 mL) and washed using NaHCO$_3$ (2 × 100 mL) followed by brine (1 × 100 mL). The organic layer was dried over Na$_2$SO$_4$, filtered, and concentrated under reduced pressure to afford the crude imine ether product as an oil (3.98 g). This was used directly without further purification.

To a solution of the crude imine ether oil (3.98 g, 15.4 mmol) in CHCl$_3$ (24 mL), L-cysteine methyl ester (3.97 g, 23.1 mmol) was added in anhydrous MeOH (18 mL) at 0 °C. The reaction mixture was stirred under an inert atmosphere at 0 °C for 2 hours after which it was allowed to warm to room temperature. After 18 hours the white suspension was concentrated under reduced pressure and purified immediately by silica gel column chromatography eluting 10–55% Et$_2$O in petroleum ether to afford **4** (2.73 g, 44% over 2 steps) as a yellow oil. ^{1}H NMR (400 MHz, CDCl$_3$) δ 5.22 (d, *J* = 9.2 Hz, 1H, NH), 5.12 (t, *J* = 1.7 Hz, 1H, C*H*COOH), 4.53–4.45 (m, 1H, CH), 3.78 (s, 3H, OCH$_3$), 3.61–3.45 (m, 2H, SCH$_2$), 1.98–1.84 (m, 1H, CH$_3$C*H*), 1.54–1.44 (m, 1H, CH*H*), 1.42 (s, 9H, C(CH$_3$)$_3$), 1.18–1.02 (m, 1H, C*H*H), 0.95 (d, *J* = 6.9 Hz, 3H, CHC*H*$_3$), 0.89 (t, *J* = 7.4 Hz, 3H, CH$_2$C*H*$_3$). ^{13}C NMR (101 MHz, CDCl$_3$) δ 176.3 (C), 171.1 (C), 155.5 (C), 79.8 (C) 77.6 (CH), 57.8 (CH), 52.8 (CH$_3$), 39.2 (CH), 35.6 (CH$_2$), 28.4 ((CH$_3$)$_3$), 24.2 (CH$_2$), 15.7 (CH$_3$), 11.9 (CH$_3$). HRMS (ESI) *m/z*: [M+H]$^+$ calculated C$_{15}$H$_{26}$N$_2$O$_4$S: 331.1686, found: 331.1694.

(*R*)-2-[1'(*S*)-(*tert*-butoxycarbonylamino)-2'(*S*)-methylbutyl]-Δ²-thiazoline-4-carboxylic acid (5).

To a solution of **4** (1.06 g, 3.21 mmol) in 1,2-dichloroethane (16 mL) was added trimethyltin hydroxide (1.74 g, 9.63 mmol). The solution was heated to 80 °C with stirring under an inert atmosphere for 2 hours. After full conversion by TLC, the mixture was concentrated under reduced pressure. The residue was then diluted with EtOAc (50 mL) and washed with 0.01 M KHSO$_4$ (3 × 50 mL). The pH of the combined aqueous layers was measured, and then gently acidified by dropwise addition of 1 M KHSO$_4$ until a pH of 3–4 was achieved. Next the combined aqueous layers were extracted once with EtOAc (100 mL). The combined organic layers were next washed further with 0.01 M KHSO$_4$ (3 × 150 mL) and brine (1 × 150 mL). The organic layer was dried over Na$_2$SO$_4$, filtered, and concentrated. For practical reasons the residue was redissolved in 1:1 [t]BuOH/H$_2$O (50 mL) and lyophilised to afford **5** (0.79 g, 78%) as a white solid. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.14 (br s, 1H, OH), 5.48 (d, *J* = 8.8 Hz, 1H, NH), 5.20 (t, *J* = 9.1 Hz, 1H, C*H*COOH), 4.50 (s, 1H, CH), 3.65 (t, *J* = 10.3 Hz, 1H, SCH*H*), 3.57 (t, *J* = 10.3 Hz, 1H, SCH*H*), 1.93 (d, *J* = 10.9 Hz, 1H, CH$_3$C*H*), 1.48 (d, *J* = 6.2 Hz, 1H, CH$_3$CH*H*), 1.43 (s, 9H, C(CH$_3$)$_3$), 1.21–1.07 (m, 1H, CH$_3$CH*H*), 0.95 (d, *J* = 7.1 Hz, 3H, CHC*H*$_3$), 0.90 (t, *J* = 5.7 Hz 3H, CH$_2$C*H*$_3$). ^{13}C NMR (101 MHz, CDCl$_3$) δ 180.6 (C), 173.0 (C), 155.8 (C), 80.4 (C), 77.2 (CH), 56.8 (CH), 38.7 (CH), 35.3 (CH$_2$), 28.4 ((CH$_3$)$_3$), 26.62 (CH$_2$), 15.7 (CH$_3$), 11.9 (CH$_3$). HRMS (ESI) *m/z*: [M+H]$^+$ calculated C$_{14}$H$_{24}$N$_2$O$_4$S: 317.1530, found: 317.1531.

Solid-Phase Peptide Synthesis

General procedure A: Peptide backbone synthesis (automated): The resin bound linear decapeptide was assembled on a CEM HT12 Liberty Blue peptide synthesiser. This commenced with Fmoc-L-Asp-OAllyl being loaded onto MBHA Rink amide resin through its side chain. The linear peptide was then extended with 9 further SPPS cycles sequentially adding: Fmoc-D-Asp(tBu)-OH, Fmoc-L-His(Trt)-OH, Fmoc-D-Phe-OH, Fmoc-L-Ile-OH, Fmoc-D-Orn(Boc)-OH, Fmoc-L-Lys(Alloc)-OH, Fmoc-L-Ile-OH, Fmoc-D-Glu(tBu)-OH, and Fmoc-L-Leu-OH. This was achieved by first swelling MBHA Rink amide resin (163 mg, 0.1 mmol) in 10 mL of DMF for 5 minutes. Fmoc deprotections were carried out in a solution of piperidine in DMF (1:4 *v/v*, 3 mL) heated to 76 °C for 15 seconds followed by 50 seconds at 90 °C. The resin was then washed with DMF (3 × 2 mL). Single amino acid coupling cycles were performed in DMF (4 mL) and mediated by DIC (0.125 mol/L, 5 eq.), Oxyma (0.125 mol/L, 5 eq.) and the respective Fmoc amino acid (0.025 mol/L, 1 eq.) at 75 °C for 15 seconds followed by 110 seconds at 90 °C. The only exception was Fmoc-L-His(Trt)-OH, where the coupling was performed at 25 °C for 2 minutes followed by 8 minutes at 50 °C. After the 10th amino acid was coupled, a final washing step was performed (3 × 2 mL DMF). At this stage the resin-bound decapeptide was removed from the peptide synthesiser, manually washed with DCM, and dried under a continuous flow of nitrogen.

General procedure B: Cyclisation (manual): The peptide-loaded resin was swelled in DCM (*ca.* 7 mL) for 10 minutes under a nitrogen atmosphere. To this was added Pd(PPh$_3$)$_4$ (30 mg, 0.03 mmol), and phenylsilane (0.30 mL, 3.0 mmol) with a flow of nitrogen providing agitation. After 1 hour, the reaction mixture was drained thoroughly washed. Firstly with DCM (5 × 10 mL), then a solution of diethyldithiocarbamic acid trihydrate sodium salt (5 mg mL^{-1} in DMF, 5 × 10 mL), and finally DMF (5 × 10 mL). After confirmation of Alloc/Allyl deprotection by LC-MS, cyclisation was effected by treatment of the peptide with 4 equivalents of BOP and 8 equivalents of DIPEA in 4 mL of DMF for 1 hour. The resin was then washed with DMF (3 × 4 mL).

General procedure C: N-terminal coupling (manual): The terminal Fmoc group was removed with piperidine in DMF (1 : 4 *v/v*, 2 × 5 mL, 1 × 5 min., 1 × 15 min.). The resin was then washed with DMF (3 × 4 mL). Next, a solution of Boc-protected aminothiazoline building block **5** (2 eq.), COMU (2 eq.), and 2,2,6,6-tetramethylpiperidine (1 eq.) in 4 mL of DMF was allowed to react for 1 minute before being added to the resin bound cyclised decapeptide. Once the reaction was complete, visible by colour change, (*ca.* 30 min.) the resin was drained and washed with DMF (3 × 5 mL).

General procedure D: Global deprotection and cleavage from resin: The completed peptide was simultaneously deprotected and cleaved from the resin by treatment with a mixture of TFA:TIPS:H$_2$O (95:2.5:2.5 *v/v/v*, 5 mL) for 30 minutes. The reaction mixture was filtered and added to a cooled mixture of MTBE/hexanes (1:1 *v/v*, 45 mL). This lead to the precipitation of the peptide which was collected by centrifugation and washed twice more with MTBE/hexanes (2 × 50 mL), yielding crude bacitracin A.

General Procedure E: Preparative HPLC purification: Bacitracin and derivatives were purified using a BESTA-Technik system with a Dr. Maisch Reprosil Gold 120 C18 column (25 × 250 mm, 10 μm) and equipped with a ECOM Flash UV detector monitoring at 214 and 254 nm. As solvent system, at a flow rate of 12 mL/min., was used: solvent A (0.1 % TFA in water/acetonitrile [95:5 *v/v*]); solvent B (0.1 % TFA in water/acetonitrile [95:5 *v/v*]). Gradient elution was as follows: 100:0 to 40:60 A/B over 80 min., 40:60 to 0:100 A/B over 1 min., 0:100 A/B for 5 min., then reversion back to 100:0 A/B over 1 min., 100:0 A/B for 3 min., total method = 90 min. After collection, fractions were frozen and lyophilised yielding pure peptide as a white powder.

Bacitracin A (1)

The peptide was prepared according to the *general procedure for synthesis of bacitracin peptides* at 0.1 mmol scale. Yield: 28 mg, 20%. HRMS (ESI) *m/z*: [M+2H]$^{2+}$ calculated for C$_{66}$H$_{103}$N$_{17}$O$_{16}$S 711.8818, found: 711.8819. HPLC R$_t$ = 14.06 min.

MIC Determinations

From glycerol stocks, bacterial strains were cultured on blood agar plates and incubated overnight at 37 °C. Following incubation, 3 mL of tryptic soy broth (TSB) was inoculated with an individual colony. The cultures were grown to exponential phase (OD_{600} = 0.5) at 37 °C. The bacterial suspensions were then diluted 100-fold in lysogeny broth supplemented with 0.3 M $ZnSO_4$ (ZnLB) to reach a bacterial cell density of 10^6 CFU mL^{-1}. In polypropylene 96-well microtiter plates, test compounds in ZnLB were added in triplicate and 2-fold serially diluted to achieve a final volume of 50 µL per well. An equal volume of bacterial suspension (10^6 CFU mL^{-1}) was added to the wells. The plates were sealed with breathable membranes and incubated at 37 °C for 18 hours with constant shaking (600 rpm). MICs were determined by visual inspection as the median of a minimum of triplicates.

Quantification of Acid Mediated Epimerisation

6 mg of purified commercially available Bacitracin A was dissolved in 2 mL of cleavage cocktail (TFA 95%, TIPS 2.5%, water 2.5%; v/v/v) and stirred. Every 15 minutes, 0.1 mL of this solution was removed and the TFA evaporated under reduced pressure. The resulting residue was then analysed by HPLC. This was performed on a Shimadzu Prominence-i LC-2030 system with a Dr. Maisch ReproSil Gold 120 C18 column (4.6 × 250 mm, 10 µm) at 30 °C and equipped with a UV detector monitoring at 214 and 254 nm. The following solvent system, at a flow rate of 1 mL/min, was used: solvent A (0.1 % TFA in water/acetonitrile 95/5); solvent B (0.1 % TFA in water/acetonitrile 5/95). Gradient elution was as follows: 100:0 (A/B) for 2 min, 100:0 to 50:50 (A/B) over 23 min, 50:50 to 0:100 (A/B) over 1 min, 0:100 (A/B) for 2 min, then reversion back to 100:0 (A/B) over 0.5 min, 100:5 (A/B) for 3.5 min, total method = 32 min.

Acknowledgements

Referenced Works

1	C. J. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. Robles Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. Kashef Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyanev, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629–655.
2	T. Roemer and C. Boone, *Nat. Chem. Biol.*, 2013, **9**, 222–231.
3	M. N. Gwynn, A. Portnoy, S. F. Rittenhouse and D. J. Payne, *Ann. N. Y. Acad. Sci.*, 2010, **1213**, 5–19.
4	V. Pavli and V. Kmetec, *J. Pharm. Biomed. Anal.*, 2001, **24**, 977–982.
5	B. A. Johnson, H. Anker and F. L. Meleney, *Science.*, 1945, **102**, 376–377.
6	G. Drapeau, E. Petitclerc, A. Toulouse and F. Marceau, *Antimicrob. Agents Chemother.*, 1992, **36**, 955–961.
7	L. J. Ming and J. D. Epperson, *J. Inorg. Biochem.*, 2002, **91**, 46–58.
8	D. Konz, A. Klens, K. Schörgendorfer and M. A. Marahiel, *Chem. Biol.*, 1997, **4**, 927–937.
9	S. A. Suleiman, F. Song, M. Su, T. Hang and M. Song, *J. Pharm. Anal.*, 2017, **7**, 48–55.
10	G. Siewert and J. L. Strominger, *Proc. Natl. Acad. Sci. U. S. A.*, 1967, **57**, 767–773.
11	K. J. Stone and J. L. Strominger, *Proc. Natl. Acad. Sci. U. S. A.*, 1971, **68**, 3223–3227.
12	D. R. Storm and J. L. Strominger, *J. Biol. Chem.*, 1973, **248**, 3940–3945.
13	N. J. Economou, S. Cocklin and P. J. Loll, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 14207–14212.
14	D. R. Storm, *Ann. N. Y. Acad. Sci.*, 1974, **235**, 387–398.
15	J. Lee, J. H. Griffin and T. I. Nicas, *J. Org. Chem.*, 1996, **61**, 3983–3986.
16	C. Pan, T. Kuranaga and H. Kakeya, *Org. Biomol. Chem.*, 2020, **18**, 8366–8370.
17	K. C. Nicolaou, A. A. Estrada, M. Zak, S. H. Lee and B. S. Safina, *Angew. Chemie - Int. Ed.*, 2005, **44**, 1378–1382.
18	K. Yonetani, Y. Hirotsu and T. Shiba, *Bull. Chem. Soc. Jpn.*, 1975, **48**, 3302–3305.
19	Y. Hirotsu, T. Shiba and T. Kaneko, *Bull. Chem. Soc. Jpn.*, 1970, **43**, 1870–1873.
20	A. C. Gaumont, M. Gulea and J. Levillain, *Chem. Rev.*, 2009, **109**, 1371–1401.

21   B. Wagner, D. Schumann, U. Linne, U. Koert and M. A. Marahiel, *J. Am. Chem. Soc.*, 2006, **128**, 10513–10520.
22   W. Konigsberg, R. J. Hill and L. C. Craig, *J. Org. Chem.*, 1961, **26**, 3867–3871.
23   R. Subirós-Funosas, L. Nieto-Rodriguez, K. J. Jensen and F. Albericio, *J. Pept. Sci.*, 2013, **19**, 408–414.
24   M. Toumi, F. Couty and G. Evano, *J. Org. Chem.*, 2008, **73**, 1270–1281.
25   M. North and G. Pattenden, *Tetrahedron*, 1990, **46**, 8267–8290.
26   N. Buijs, H. C. Vlaming, M. J. van Haren and N. I. Martin, *ChemBioChem*, 2022, e202200547

2

Supplementary Figures

Figure S1. Purified bacitracin diastereomers showing analytical HPLC traces and recorded HRMS data. Detailed experimental procedures are provided in the supporting information accompanying reference [26].

Scheme S1. Proposed mechanism of thiazoline epimerisation under **(A)** base-mediated conditions, and **(B)** acid-mediated conditions.

NMR Assignment Synthetic and Natural Bacitracin A

Table S1. Full NMR assignment of synthetic bacitracin A (BacA$_D$).

	Residue	NH	H$_\alpha$(C$_\alpha$)	H$_\beta$(C$_\beta$)	Other
1	1-Ile	N.D.	4.28 (56.1)	1.89 (36.7)	C$_{\gamma 1}$H$_2$: 1.21, 1.45 (23.9) C$_{\gamma 2}$H$_3$ (d) : 0.96 (13.8) C$_\delta$H$_3$ (t) : 0.88 (11.4)
2	2-Cys	-	5.17 (77.0)	3.56, 3.70 (35.8)	
3	3-Leu	7.83	4.48 (50.8)	1.46 (40.8)	C$_\gamma$H: 1.48 (23.9) C$_{\delta 1}$H$_3$: 0.83 (21.2) C$_{\delta 2}$H$_3$: 0.86 (22.7)
4	4-Glu	8.40	4.40 (51.6)	1.74, 1.89 (27.7)	C$_\gamma$H$_2$: 2.18 (29.8)
5	5-Ile	7.87	4.23 (56.3)	1.78 (36.4)	C$_{\gamma 1}$H$_2$: 1.07, 1.35 (23.6) C$_{\gamma 2}$H$_3$ (d) : 0.80 (15.1) C$_\delta$H$_3$ (t) : 0.78 (10.5)
6	6-Lys	8.31	4.17 (52.6)	1.51, 1.60 (31.2)	C$_\gamma$H$_2$: 1.21 (22.0) C$_\delta$H$_2$: 1.35 (28.1) C$_\epsilon$H$_2$: 3.01, 2.94 (37.9) NH: 7.76
7	7-Orn	7.53	4.46 (50.7)	1.59, 1.41 (30.1)	CγH$_2$: 1.41, 1.45 (23.0) C$_\delta$H$_2$: 2.74 (38.2) NH$_2$: 7.74
8	8-Ile	8.04	4.29 (56.1)	1.42 (36.8)	C$_{\gamma 1}$H$_2$: 0.70, 0.78 (22.8) C$_{\gamma 2}$H$_3$ (d) : 0.47 (14.9) C$_\delta$H$_3$ (t) : 0.49 (10.9)
9	9-Phe	8.41	4.68 (53.5)	2.75, 2.46 (38.1)	*Ortho*: 7.23 (128.9) *Meta*: 7.21 (127.7) *Para*: 7.13 (126.0)
10	10-His	8.67	4.86 (50.6)	3.02, 2.83 (28.4)	C2H: 7.29 (116.7) C4H: 8.95 (133.5) N3H: 12.26 N5H: 8.45
11	11-Asp	8.47	4.74 (49.0)	2.63, 2.45 (37.2)	
12	12-Asn	8.32	4.52 (49.6)	2.47, 2.35 (37.3)	NH$_2$: 6.88, 7.30

N.D.: Not detected under these experimental conditions.

Table S2. Full NMR assignment of natural bacitracin A (commercially sourced).

	Residue	NH	$H_\alpha(C_\alpha)$	$H_\beta(C_\beta)$	Other
1	**1-Ile**	N.D.	4.28 (56.2)	1.89 (36.7)	$C_{\gamma 1}H_2$: 1.21, 1.45 (24.0) $C_{\gamma 2}H_3$ (d) : 0.97 (13.9) $C_\delta H_3$ (t) : 0.88 (11.4) NH_3: 8.45
2	**2-Cys**	-	5.17 (77.1)	3.56, 3.70 (35.9)	
3	**3-Leu**	7.82	4.48 (50.9)	1.47 (40.9)	$C_\gamma H$: 1.47 (24.0) $C_{\delta 1}H_3$: 0.84 (21.4) $C_{\delta 2}H_3$: 0.86 (22.8)
4	**4-Glu**	8.38	4.40 (51.6)	1.74, 1.90 (27.7)	$C_\gamma H_2$: 2.19 (29.9)
5	**5-Ile**	7.85	4.23 (56.4)	1.78 (36.4)	$C_{\gamma 1}H_2$: 1.07, 1.35 (23.7) $C_{\gamma 2}H_3$ (d) : 0.81 (15.1) $C_\delta H_3$ (t) : 0.79 (10.6)
6	**6-Lys**	8.29	4.17 (52.7)	1.52, 1.61 (31.3)	$C_\gamma H_2$: 1.21 (22.0) $C_\delta H_2$: 1.35 (28.1) $C_\varepsilon H_2$: 3.01, 2.94 (38.0) NH: 7.74
7	**7-Orn**	7.53	4.46 (50.8)	1.61, 1.41 (30.2)	$C_\gamma H_2$: 1.42, 1.45 (23.0) $C_\delta H_2$: 2.75 (38.2) NH_2: 7.72
8	**8-Ile**	8.03	4.29 (56.2)	1.42 (36.8)	$C_{\gamma 1}H_2$: 0.71, 0.81 (22.9) $C_{\gamma 2}H_3$ (d) : 0.47 (14.9) $C_\delta H_3$ (t) : 0.50 (10.9)
9	**9-Phe**	8.40	4.68 (53.5)	2.76, 2.46 (38.1)	*Ortho*: 7.23 (129.0) *Meta*: 7.21 (127.7) *Para*: 7.13 (126.0)
10	**10-His**	8.64	4.85 (50.7)	3.03, 2.83 (28.5)	C2H: 7.28 (116.8) C4H: 8.91 (133.6) N3H: 12.19 N5H: 8.45
11	**11-Asp**	8.46	4.73 (49.1)	2.63, 2.46 (37.2)	
12	**12-Asn**	8.30	4.52 (49.8)	2.47, 2.36 (37.3)	NH_2: 6.86, 7.28

N.D.: Not detected under these experimental conditions.

NMR experiments were performed on a Bruker AV-850 spectrometer. In addition to 1D ^{1}H, HSQC, TOCSY, NOESY and COSY 2D spectra were measured in DMSO-d_6. The chemical shifts are noted as δ-values in parts per million (ppm) relative to the signal of DMSO-d_6 for ^{1}H NMR (δ = 2.50 ppm) and relative to the solvent signal of DMSO-d_6 for ^{13}C NMR (δ = 39.52 ppm). Coupling constants (J) are given in Hz. Full spectra are provided in the supporting information accompanying reference [26].